Reji Reshma Mahima, V M Berlin Grace
Department of Biotechnology, Karunya University, Coimbatore-641 114, Tamil Nadu, India.
Department of Biotechnology, Karunya University, Karunya Nagar, Coimbatore - 641 114. Tamil Nadu, India.
Anticancer Agents Med Chem. 2017;17(6):875-884. doi: 10.2174/1871520616666160927103458.
The high mortality rate of lung cancer is highly associated with faster metastasis spread. All Trans Retinoic Acid (ATRA), being the first choice drug for leukemia therapy is now under intense study for its therapeutic efficiency in other solid cancers.
This study was aimed to investigate the anti-metastasis activity of free ATRA and liposome entrapped ATRA (5:4:1) in the experimental C57BL/6 mice model developed by the injection of B16F10 cell line into the tail vein.
The ATRA drug was given via i.p for 21 days. The visual lung and liver metastatic tumor nodules were noted. Various biochemical markers of cancer metastasis in the serum as well as tissues were also analyzed after sacrifice.
Tumor nodules have significantly decreased in ATRA treatment groups (32.83 ± 1.83 for free ATRA, 23 ± 2.36 for DSPC Lipo-ATRA) when compared with metastasis control (63.16 ± 2.9) in the lungs. Among the treatment groups, the DSPC lipo-ATRA treated group showed a significant tumor growth inhibition (63.6%) than that of in the free ATRA treated groups (48%). Similar anti-metastatic effect was observed in liver also. Furthermore lipo-ATRA has shown a significant change in the levels of biochemical cancer markers analyzed in this study.
Our results concluded that the liposome encapsulated ATRA has an enhanced anti-metastasis potency than the free ATRA during B16F10 metastatic cell line implantation.
肺癌的高死亡率与转移扩散速度加快密切相关。全反式维甲酸（ATRA）作为白血病治疗的首选药物，目前正因其在其他实体癌中的治疗效果而受到深入研究。
本研究旨在研究游离ATRA和脂质体包裹的ATRA（5:4:1）在通过尾静脉注射B16F10细胞系建立的C57BL/6实验小鼠模型中的抗转移活性。
通过腹腔注射给予ATRA药物，持续21天。记录肉眼可见的肺和肝转移瘤结节。在处死小鼠后，还分析了血清和组织中各种癌症转移的生化标志物。
与肺部转移对照组（63.16±2.9）相比，ATRA治疗组的肿瘤结节显著减少（游离ATRA组为32.83±1.83，DSPC脂质体包裹的ATRA组为23±2.36）。在各治疗组中，DSPC脂质体包裹的ATRA治疗组的肿瘤生长抑制率（63.6%）显著高于游离ATRA治疗组（48%）。在肝脏中也观察到了类似的抗转移效果。此外，脂质体包裹的ATRA在本研究中分析的生化癌症标志物水平上显示出显著变化。
我们的结果表明，在B16F10转移细胞系植入过程中，脂质体包裹的ATRA比游离ATRA具有更强的抗转移能力。
